相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Exosomes Containing LINC00461 Originated from Multiple Myeloma Inhibit the Osteoblast Differentiation of Bone Mesenchymal Stem Cells via Sponging miR-324-3p
Yang Wu et al.
JOURNAL OF HEALTHCARE ENGINEERING (2022)
DOT1L inhibition blocks multiple myeloma cell proliferation by suppressing IRF4-MYC signaling
Kazuya Ishiguro et al.
HAEMATOLOGICA (2019)
Identification and characterization of HLA-A24-specific XBP1, CD138 (Syndecan-1) and CS1 (SLAMF7) peptides inducing antigens-specific memory cytotoxic T lymphocytes targeting multiple myeloma
J. Bae et al.
LEUKEMIA (2018)
Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma
A. Gulla et al.
LEUKEMIA (2018)
Targeting signaling pathways in multiple myeloma: Pathogenesis and implication for treatments
Jingping Hu et al.
CANCER LETTERS (2018)
Immunomodulatory drugs downregulate IKZF1 leading to expansion of hematopoietic progenitors with concomitant block of megakaryocytic maturation
Ailing Liu et al.
HAEMATOLOGICA (2018)
NCCN Guidelines (R) Insights Multiple Myeloma, Version 3.2018 Featured Updates to the NCCN Guidelines
Shaji K. Kumar et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study
Noopur Raje et al.
LANCET ONCOLOGY (2018)
Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma
Xiaohui Zhang et al.
LEUKEMIA (2018)
NS-018 reduces myeloma cell proliferation and suppresses osteolysis through inhibition of the JAK2 and Src signaling pathways
Ayumi Honda et al.
BLOOD CANCER JOURNAL (2018)
Immunomodulatory drugs downregulate IKZF1 leading to expansion of hematopoietic progenitors with concomitant block of megakaryocytic maturation
Ailing Liu et al.
HAEMATOLOGICA (2018)
IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos
Pasquale L. Fedele et al.
BLOOD (2018)
Bortezomib Targets Sp Transcription Factors in Cancer Cells
Keshav Karki et al.
MOLECULAR PHARMACOLOGY (2018)
The biological significance of histone modifiers in multiple myeloma: clinical applications
Hiroto Ohguchi et al.
BLOOD CANCER JOURNAL (2018)
Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma A Nonrandomized Clinical Trial
Ajay K. Nooka et al.
JAMA ONCOLOGY (2018)
Growth factor independence 1 expression in myeloma cells enhances their growth, survival, and osteoclastogenesis
Daniela N. Petrusca et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma
Mariateresa Fulciniti et al.
CELL REPORTS (2018)
IMiD compounds affect CD34+ cell fate and maturation via CRBN-induced IKZF1 degradation
Shirong Li et al.
BLOOD ADVANCES (2018)
Targeting mutant p53 for efficient cancer therapy
Vladimir J. N. Bykov et al.
NATURE REVIEWS CANCER (2018)
The NF-κB Activating Pathways in Multiple Myeloma
Payel Roy et al.
BIOMEDICINES (2018)
The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment
F. Fan et al.
LEUKEMIA (2017)
Preclinical activity of CPI-0610, a novel small-molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma
K. T. Siu et al.
LEUKEMIA (2017)
Differentiation stage of myeloma plasma cells: biological and clinical significance
B. Paiva et al.
LEUKEMIA (2017)
Fra-2 regulates B cell development by enhancing IRF4 and Foxo1 transcription
Kenia Ubieta et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2017)
Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors
William McCoull et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
KDM6B modulates MAPK pathway mediating multiple myeloma cell growth and survival
H. Ohguchi et al.
LEUKEMIA (2017)
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours
Loren M. Lasko et al.
NATURE (2017)
Functions of bromodomain-containing proteins and their roles in homeostasis and cancer
Takao Fujisawa et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2017)
PU.1 acts as tumor suppressor for myeloma cells through direct transcriptional repression of IRF4
N. Ueno et al.
ONCOGENE (2017)
Logic programming reveals alteration of key transcription factors in multiple myeloma
Bertrand Miannay et al.
SCIENTIFIC REPORTS (2017)
Requirement for the Transcription Factor LSIRF/IRF4 for Mature B and T Lymphocyte Function
Hans-Willi Mittrucker et al.
JOURNAL OF IMMUNOLOGY (2017)
Loss of FAM46C Promotes Cell Survival in Myeloma
Yuan Xiao Zhu et al.
CANCER RESEARCH (2017)
EZH2 or HDAC1 Inhibition Reverses Multiple Myeloma-Induced Epigenetic Suppression of Osteoblast Differentiation
Juraj Adamik et al.
MOLECULAR CANCER RESEARCH (2017)
Transcriptional Addiction in Cancer
James E. Bradner et al.
CELL (2017)
Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells
Michele Cea et al.
BLOOD (2016)
Immunomodulatory drugs act as inhibitors of DNA methyltransferases and induce PU.1 up-regulation in myeloma cells
Shinya Endo et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2016)
Targeting transcription factors by small compounds-Current strategies and future implications
Judith Hagenbuchner et al.
BIOCHEMICAL PHARMACOLOGY (2016)
MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma
Ya-Wei Qiang et al.
BLOOD (2016)
Aiolos collaborates with Blimp-1 to regulate the survival of multiple myeloma cells
K-H Hung et al.
CELL DEATH AND DIFFERENTIATION (2016)
The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma
Charlotte Pawlyn et al.
CLINICAL CANCER RESEARCH (2016)
3-Formylchromone inhibits proliferation and induces apoptosis of multiple myeloma cells by abrogating STAT3 signaling through the induction of PIAS3
Jeong-Hyeon Ko et al.
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY (2016)
Histone deacetylase inhibitors in multiple myeloma: from bench to bedside
Takeshi Harada et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2016)
Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma
Nicola Amodio et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Epigenetic modulators, modifiers and mediators in cancer aetiology and progression
Andrew P. Feinberg et al.
NATURE REVIEWS GENETICS (2016)
The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival
Hiroto Ohguchi et al.
NATURE COMMUNICATIONS (2016)
Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death
Yuko Mishima et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Metabolic Signature Identifies Novel Targets for Drug Resistance in Multiple Myeloma
Patricia Maiso et al.
CANCER RESEARCH (2015)
Ibrutinib inhibits BTK-driven NF-κB p65 activity to overcome bortezomib-resistance in multiple myeloma
Megan Y. Murray et al.
CELL CYCLE (2015)
The RUNX1-PU.1 axis in the control of hematopoiesis
Maria Rosaria Imperato et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2015)
Advances in the pathogenesis and diagnosis of multiple myeloma
M. Chesi et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2015)
Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo
E. Morelli et al.
LEUKEMIA (2015)
Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma
S. Kikuchi et al.
LEUKEMIA (2015)
APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma
Brian A. Walker et al.
NATURE COMMUNICATIONS (2015)
Transcriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth
Subrahmanya D. Vallabhapurapu et al.
NATURE COMMUNICATIONS (2015)
Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma
Matthew B. Siegel et al.
ONCOTARGET (2015)
Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762
Aristeidis Chaidos et al.
BLOOD (2014)
PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance
Benoit Tessoulin et al.
BLOOD (2014)
Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma
Yuan Xiao Zhu et al.
BLOOD (2014)
The AP-1 transcription factor Fra1 inhibits follicular B cell differentiation into plasma cells
Bettina Groetsch et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
Histone deacetylase 3 as a novel therapeutic target in multiple myeloma
J. Minami et al.
LEUKEMIA (2014)
Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma
M. Affer et al.
LEUKEMIA (2014)
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Jan Kroenke et al.
SCIENCE (2014)
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Gang Lu et al.
SCIENCE (2014)
GSK3-mediated MAF phosphorylation in multiple myeloma as a potential therapeutic target
N. I. Herath et al.
BLOOD CANCER JOURNAL (2014)
Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma
Enrica Borsi et al.
ONCOTARGET (2014)
MYC regulates the non-coding transcriptome
Jonathan R. Hart et al.
ONCOTARGET (2014)
Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma
Martin F. Kaiser et al.
BLOOD (2013)
Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma
Chungyee Leung-Hagesteijn et al.
CANCER CELL (2013)
miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells
Nicola Amodio et al.
CELL CYCLE (2013)
Repression of the Transcription Factor Bach2 Contributes to Predisposition of IgG1 Memory B Cells toward Plasma Cell Differentiation
Kohei Kometani et al.
IMMUNITY (2013)
Phase Ib Study of Panobinostat and Bortezomib in Relapsed or Relapsed and Refractory Multiple Myeloma
Jesus F. San-Miguel et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Targeting p53 by small molecules in hematological malignancies
Manujendra N. Saha et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
Myeloma Is Characterized by Stage-Specific Alterations in DNA Methylation That Occur Early during Myelomagenesis
Christoph J. Heuck et al.
JOURNAL OF IMMUNOLOGY (2013)
Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction
P. Storti et al.
LEUKEMIA (2013)
GENE REGULATION From genetic variation to phenotype via chromatin
Hannah Stower
NATURE REVIEWS GENETICS (2013)
Mithramycin Exerts an Anti-Myeloma Effect and Displays Anti-Angiogenic Effects through Up-Regulation of Anti-Angiogenic Factors
Eleonore Otjacques et al.
PLOS ONE (2013)
A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases
F. Hayakawa et al.
BLOOD CANCER JOURNAL (2013)
Expression of XBP1s in bone marrow stromal cells is critical for myeloma cell growth and osteoclast formation
Guoshuang Xu et al.
BLOOD (2012)
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma
Loredana Santo et al.
BLOOD (2012)
Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma
Naoya Mimura et al.
BLOOD (2012)
Drug Resistance to Inhibitors of the Human Double Minute-2 E3 Ligase Is Mediated by Point Mutations of p53, but Can Be Overcome with the p53 Targeting Agent RITA
Richard J. Jones et al.
MOLECULAR CANCER THERAPEUTICS (2012)
SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status
L. Lopez-Corral et al.
LEUKEMIA (2012)
The cell-cycle regulator c-Myc is essential for the formation and maintenance of germinal centers
Dinis Pedro Calado et al.
NATURE IMMUNOLOGY (2012)
The genetic architecture of multiple myeloma
Gareth J. Morgan et al.
NATURE REVIEWS CANCER (2012)
A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression
Christina M. Annunziata et al.
BLOOD (2011)
IMiD immunomodulatory compounds block C/EBPβ translation through eIF4E down-regulation resulting in inhibition of MM
Shirong Li et al.
BLOOD (2011)
Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease
Sonia D'Souza et al.
BLOOD (2011)
The Pax-5 Gene: A Pluripotent Regulator of B-cell Differentiation and Cancer Disease
Pierre O'Brien et al.
CANCER RESEARCH (2011)
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake E. Delmore et al.
CELL (2011)
Significant Biological Role of Sp1 Transactivation in Multiple Myeloma
Mariateresa Fulciniti et al.
CLINICAL CANCER RESEARCH (2011)
The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival
A. Scuto et al.
LEUKEMIA (2011)
Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma
W-J Chng et al.
LEUKEMIA (2011)
Targeting MYC dependence in cancer by inhibiting BET bromodomains
Jennifer A. Mertz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
DNA methylation analysis of tumor suppressor genes in monoclonal gammopathy of undetermined significance
Carmen Stanganelli et al.
ANNALS OF HEMATOLOGY (2010)
Bone development and inflammatory disease is regulated by AP-1 (Fos/Jun)
E. F. Wagner
ANNALS OF THE RHEUMATIC DISEASES (2010)
Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia
Rekha Pal et al.
BLOOD (2010)
XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments
Tina Bagratuni et al.
BLOOD (2010)
A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells
Teru Hideshima et al.
BLOOD (2010)
Overexpression of PAX5 induces apoptosis in multiple myeloma cells
Maryse Proulx et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2010)
Effectors and memories: Bcl-6 and Blimp-1 in T and B lymphocyte differentiation
Shane Crotty et al.
NATURE IMMUNOLOGY (2010)
C/EBPβ regulates transcription factors critical for proliferation and survival of multiple myeloma cells
Rekha Pal et al.
BLOOD (2009)
PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain
Jeremy M. R. Lambert et al.
CANCER CELL (2009)
Targeting Angiogenesis via a c-Myc/Hypoxia-Inducible Factor-1α-Dependent Pathway in Multiple Myeloma
Jing Zhang et al.
CANCER RESEARCH (2009)
DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival
Timothy R. Peterson et al.
CELL (2009)
Sp1 Phosphorylation and Its Regulation of Gene Transcription
Nicole Y. Tan et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
A census of human transcription factors: function, expression and evolution
Juan M. Vaquerizas et al.
NATURE REVIEWS GENETICS (2009)
STATs in cancer inflammation and immunity: a leading role for STAT3
Hua Yu et al.
NATURE REVIEWS CANCER (2009)
Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3
Erik A. Nelson et al.
BLOOD (2008)
Clinical and biological significance of RAS mutations in multiple myeloma
W. J. Chng et al.
LEUKEMIA (2008)
IRF4 addiction in multiple myeloma
Arthur L. Shaffer et al.
NATURE (2008)
Expression of MUM1/IRF4 mRNA as a prognostic marker in patients with multiple myeloma
D. Heintel et al.
LEUKEMIA (2008)
Inhibition of adhesive interaction between multiple myeloma and bone marrow stromal cells by PPARγ cross talk with NF-κB and C/EBPβ
Li Hua Wang et al.
BLOOD (2007)
The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 α (HIF-1α) activity:: involvement in myeloma-induced angiogenesis
Simona Colla et al.
BLOOD (2007)
Down-regulation of PU.1 by methylation of distal regulatory elements and the promoter is required for myeloma cell growth
Hiro Tatetsu et al.
CANCER RESEARCH (2007)
Osteopontin dysregulation in multiple myeloma
Davide F. Robbiani et al.
HEMATOLOGICAL ONCOLOGY (2007)
Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma
Klaus Podar et al.
CANCER RESEARCH (2007)
The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis
Daniel R. Carrasco et al.
CANCER CELL (2007)
Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1
G Anderson et al.
BLOOD (2006)
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma
T Hideshima et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation
DR Hodge et al.
CANCER RESEARCH (2005)
Regulation of plasma-cell development
M Shapiro-Shelef et al.
NATURE REVIEWS IMMUNOLOGY (2005)
p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation
H Chang et al.
BLOOD (2005)
Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma
EM Hurt et al.
CANCER CELL (2004)
Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions
H Chang et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress
Y Kawaguchi et al.
CELL (2003)
AP-1: A double-edged sword in tumorigenesis
R Eferl et al.
NATURE REVIEWS CANCER (2003)
The X-box binding protein-1 transcription factor is required for plasma cell differentiation and the unfolded protein response
NN Iwakoshi et al.
IMMUNOLOGICAL REVIEWS (2003)
Transcription factors as targets for cancer therapy
JE Darnell
NATURE REVIEWS CANCER (2002)
Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells
S Le Gouill et al.
LEUKEMIA (2002)
CCAAT/enhancer-binding proteins: structure, function and regulation
DP Ramji et al.
BIOCHEMICAL JOURNAL (2002)
Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors
H Avet-Loiseau et al.
BLOOD (2001)
分享论文
